Anti-Human TNF Therapeutic Single Domain Antibody (VL18-3L-VL11) (CAT#: TAB-415CQ)

Figure 1 Illustrate results of binding assays and pharmacokinetics of a VL-VL dimer of the invention.

Illustrate relative binding and specificity of the dimer to TNF molecules of various species by ELISA

Figure 2 Illustrate results of binding assays and pharmacokinetics of a VL-VL dimer of the invention.

Illustrate relative binding and specificity of the dimer to TNF molecules of various species by ELISA

Figure 3 Illustrate results of binding assays and pharmacokinetics of a VL-VL dimer of the invention.

Illustrates pharmacokinetics of VL-VL constructs (VL18-3L-VL11 and VL18-3L-VL11-PEP) tested by administration to Wistar female rats to determine the serum half-life thereof in vivo

Figure 4 Illustrates results of an assay for neutralization of TNF-alpha dependent cytolytic activity using VL-VL dimers of the invention, which shows that the dimers protected L929 cells from TNF-induced cytotoxicity.

Figure 5Illustrates therapeutic effect of VL-VL dimers of the invention in an established rat adjuvant-induced arthritis model (AIA) based on clinical assessment of four limbs.

Figure 6 Illustrates therapeutic effect of VL-VL dimers of the invention in an established rat adjuvant-induced arthritis model (AIA) based on changes in hind ankle swellings.